IKT (Inhibikase Therapeutics) Common Stock: $0.13 Mil (As of Mar. 2026)


IKT Inhibikase Therapeutics Inc IKT
28 GF Score
Price $2.04
! 1 Warning Sign
View Full Analysis

What is Inhibikase Therapeutics Common Stock?

Inhibikase Therapeutics IKT +3.80% 28 Common Stock is $0.13 Mil as of Mar. 2026. GuruFocus rates IKT with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Inhibikase Therapeutics's quarterly common stock increased from Sep. 2025 ($0.08 Mil) to Dec. 2025 ($0.13 Mil) but then stayed the same from Dec. 2025 ($0.13 Mil) to Mar. 2026 ($0.13 Mil).

Inhibikase Therapeutics's annual common stock increased from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.07 Mil) and increased from Dec. 2024 ($0.07 Mil) to Dec. 2025 ($0.13 Mil).

Inhibikase Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Inhibikase Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibikase Therapeutics Common Stock Chart

Inhibikase Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial 0.03 0.00 0.01 0.07 0.13

Inhibikase Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.08 0.08 0.13 0.13
IKT
28GF Score
Inhibikase Therapeutics Inc IKT
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inhibikase Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.13 Mil mean?
Inhibikase Therapeutics (IKT) has a Common Stock of $0.13 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Inhibikase Therapeutics and its competitors.
Is Inhibikase Therapeutics' Common Stock too high?
Inhibikase Therapeutics' current Common Stock is $0.13 Mil. Overall, Inhibikase Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' Common Stock compare to FHTX and OBIO?
Inhibikase Therapeutics' Common Stock of $0.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Inhibikase Therapeutics and its competitors. Inhibikase Therapeutics's current Common Stock is $0.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current Common Stock of $0.13 Mil. The current Common Stock is $0.13 Mil. Inhibikase Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current Common Stock is $0.13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inhibikase Therapeutics Business Description

Address 1000 N. West Street, Suite 1200, Wilmington, DE, USA, 19801
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
28GF Score

Get the complete analysis for IKT

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.04
Price